Exhibit 99.3

 

THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES

UNAUDITED PRO FORMA

CONDENSED COMBINED FINANCIAL STATEMENTS

 

 

On July 17, 2019, The Joint Corp. (the “Company”) completed the purchase of three franchisee clinics from its stockholders (the “acquisition”), which consisted of: TJ of Savannah – Twelve Oaks, LLC, a Georgia limited liability company (“TJS”), TJ of Pooler, LLC, a Georgia limited liability company (“TJP”), and TJ of Bluffton, LLC, a South Carolina limited liability company (“TJB”) (TJS, TJP and TJB are referred to herein collectively, as the “Meglin Clinics”). The purchase price of $1,650,000 consisted of $1,500,000 paid in cash and a $150,000 note issued to the seller pursuant to the terms and conditions set forth in the Share Purchase Agreement. The Share Purchase Agreement was filed with the Securities and Exchange Commission (the “SEC”) as an exhibit to the Company’s Current Report on Form 8-K filed on July 23, 2019.

 

Included herein are the unaudited pro forma condensed combined financial statements, which are not necessarily indicative of what the Company’s financial position or results of operations would have been had the Company completed the acquisition at the dates indicated. In addition, the unaudited pro forma condensed combined financial information does not purport to project the future financial position or operating results of the Company after the acquisition. The pro forma information is based on the assumptions, adjustments and eliminations described in the accompanying notes to the unaudited pro forma condensed combined financial statements, which form an integral part of the statements.

 

The following unaudited pro forma condensed combined financial statements combine the historical consolidated financial statements of the Company and the historical financial statements of the Meglin clinics adjusted to give effect to the impact of the acquisition and related financing transactions. The unaudited pro forma condensed combined balance sheet presents the combined financial position giving effect to the acquisition and related financing transactions as if they had occurred on June 30, 2019. Because the Company acquired only certain assets from the Meglin Clinics, the Company have presented the acquisition of such assets in the pro forma adjustments column. The assets acquired were the assets that derived all of Meglin Clinics’ revenue, and therefore, the Company has included a separate column for the combined statements of operations pro forma presentation. The unaudited pro forma condensed combined statements of operations for the six months ended June 30, 2019 and for the year ended December 31, 2018 present the combined results of operations as if the acquisition had occurred on January 1, 2018. These unaudited pro forma condensed combined financial statements have been prepared in accordance with Regulation S-X Article 11.

 

These unaudited pro forma condensed combined financial statements should be read in connection with:

 

·Separate historical financial statements of the Company as of and for the year ended December 31, 2018, which are incorporated by reference to its Annual Report on Form 10-K; and
·Separate historical financial statements of the Company as of and for the six months ended June 30, 2019, which are incorporated by reference to its Quarterly Report on Form 10-Q for the six months ended June 30, 2019.

 

 

1

 

 

THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES

UNAUDITED PRO FORMA

CONDENSED COMBINED BALANCE SHEET

 

As of June 30, 2019

 

   The Joint Corp.  Pro Forma Adjustments    Pro Forma Condensed Combined
ASSETS                 
Current assets:                 
Cash and cash equivalents  $9,485,212   $(1,500,000) (a)   $7,985,212 
Restricted cash   129,220    -      129,220 
Accounts receivable, net   1,033,479    -      1,033,479 
Income taxes receivable   -    -      - 
Notes receivable - current portion   163,573    -      163,573 
Deferred franchise costs - current portion   710,796    (4,590) (g)   706,206 
Prepaid expenses and other current assets   887,676    -      887,676 
Total current assets   12,409,956    (1,504,590)     10,905,366 
Property and equipment, net   4,963,037    48,418 (b)   5,011,455 
Operating lease right-of-use asset   10,030,737    511,257 (h)   10,615,386 
Notes receivable, net of current portion   41,683    -      41,683 
Deferred franchise costs, net of current portion   3,485,644    (10,429) (g)    3,475,215 
Intangible assets, net   1,975,835    1,072,000 (c)   3,047,835 
Goodwill   3,225,145    483,862 (d)   3,635,615 
Deposits and other assets   337,379    -      337,379 
Total assets  $36,469,416   $600,518     $37,069,934 
                  
LIABILITIES AND STOCKHOLDERS' EQUITY                 
Current liabilities:                 
Accounts payable  $1,199,341   $-     $1,199,341 
Accrued expenses   178,949    -      178,949 
Co-op funds liability   129,220    -      129,220 
Payroll liabilities   1,602,916    -      1,602,916 
Notes payable - current portion   1,000,000    150,000 (a)   1,150,000 
Operating lease liability - current portion   1,827,233    86,815 (h)   1,914,048 
Finance lease liability - current portion   23,075    -      23,075 
Deferred franchise revenue - current portion   2,697,669    (8,700) (f)   2,688,969 
Deferred revenue from company clinics   2,677,782    53,928 (e)   2,731,710 
Other current liabilities   540,279    -      540,279 
Total current liabilities   11,876,464    282,043      12,158,507 
Operating lease liability - net of current portion   9,049,948    338,243 (h)   9,388,191 
Finance lease liability - net of current portion   46,826    -      46,826 
Deferred franchise revenue, net of current portion   12,652,780    (19,768) (f)   12,633,012 
Deferred tax liability   83,294    -      83,294 
Other liabilities   27,230    -      27,230 
Total liabilities   33,736,542    600,518      34,337,060 
Commitments and contingencies                 
Stockholders' equity:                 
Series A preferred stock, $0.001 par value; 50,000 shares authorized, 0 issued and outstanding, as of December 31, 2018 and 2017   -    -      - 
Common stock   13,838    -      13,838 
Additional paid-in capital   38,779,538    -      38,779,538 
Treasury stock   (90,856)   -      (90,856)
Accumulated deficit   (35,969,746)   -      (35,969,746)
Total The Joint Corp. stockholders' equity   2,732,774    -      2,732,774 
Non-controlling Interest   100    -      100 
Total equity   2,732,874    -      2,732,874 
Total liabilities and stockholders' equity  $36,469,416   $600,518     $37,069,934 

 

2

 

THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES

UNAUDITED PRO FORMA

CONDENSED COMBINED STATEMENTS OF OPERATIONS

 

Year Ended December 31, 2018

 

   The Joint Corp. (as adjusted)  Meglin Clinics  Pro Forma Adjustments    Pro Forma Adjustments  Pro Forma Adjustments  Pro Forma Condensed Combined
Revenues:                                
Revenues from company-owned or managed clinics  $19,545,276   $1,477,588   $-     $-   $-   $21,022,864 
Royalty fees   10,141,036    -    (135,412) (i)   -    -    10,005,624 
Franchise fees   1,688,039    -    43,983 (f)   (8,700)(j)   -    1,723,322 
Advertising fund revenue   2,862,244    -    -      -    -    2,862,244 
Software fees   1,290,135    -    (9,900) (k)   -    -    1,280,235 
Regional developer fees   599,370    -    -      -    -    599,370 
Other revenues   535,560    -    -      -    -    535,560 
Total revenues   36,661,660    1,477,588    (101,329)     (8,700)   -    38,029,219 
Cost of revenues:                                
Franchise cost of revenues   3,956,530    -    18,615 (g)   -    -    3,975,145 
IT cost of revenues   353,719    -    -      -    -    353,719 
Total cost of revenues   4,310,249    -    18,615      -    -    4,328,864 
Selling and marketing expenses   4,819,555    71,792    -      -    -    4,891,347 
Depreciation and amortization   1,556,240    44,048    368,833 (c)   (8,700)(j)   -    1,960,421 
General and administrative expenses   25,238,121    1,203,933    43,983 (f)   (135,412)(i)   (9,900)(k)   26,340,725 
Total selling, general and administrative expenses   31,613,916    1,319,773    412,816      (144,112)   (9,900)   33,192,493 
Net (gain) loss on disposition or impairment   593,960    -    -      -    -    593,960 
Income (loss) from operations   143,535    157,815    (532,760)     135,412    9,900    (86,098)
                                 
Other income (expense):                                
Bargain purchase gain   13,198    -    -      -    -    13,198 
Other income (expense), net   (47,765)   (1,391)   -      -    -    (49,156)
Total other income (expense)   (34,567)   (1,391)   -      -    -    (35,958)
                                 
Income (loss) before income tax expense   108,968    156,424    (532,760)     135,412    9,900    (122,056)
                                 
Income tax benefit   37,728    -    - (l)   -    -    37,728 
                                 
Net income (loss) and comprehensive income (loss)  $146,696   $156,424   $(532,760)    $135,412   $9,900   $(84,328)
                                 
Earnings (loss) per share:                                
                                 
Basic earnings (loss) per share  $0.01                         $(0.01)
Diluted earnings (loss) per share  $0.01                         $(0.01)
                                 
Basic weighted average shares   13,669,107                          13,669,107 
Diluted weighted average shares   14,031,717                          14,031,717 

 

3

 

 

THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES

UNAUDITED PRO FORMA

CONDENSED COMBINED STATEMENTS OF OPERATIONS

 

Six Months Ended June 30, 2019

 

 

   The Joint Corp.  Meglin Clinics  Pro Forma Adjustments    Pro Forma Adjustments  Pro Forma Condensed Combined
Revenues:                           
Revenues from company-owned or managed clinics  $11,416,365   $822,725   $-     $-   $12,239,090 
Royalty fees   6,290,346    -    (74,467) (i)   -    6,215,879 
Franchise fees   864,339    -    (4,350) (j)   -    859,989 
Advertising fund revenue   1,819,367    -    -      -    1,819,367 
Software fees   742,361    -    (4,950) (k)   -    737,411 
Regional developer fees   384,381    -    -      -    384,381 
Other revenues   332,197    -    -      -    332,197 
Total revenues   21,849,356    822,725    (83,767)     -    22,588,314 
Cost of revenues:                           
Franchise cost of revenues   2,315,431    -    (2,295) (g)   -    2,313,136 
IT cost of revenues   189,659    -    -      -    189,659 
Total cost of revenues   2,505,090    -    (2,295)     -    2,502,795 
Selling and marketing expenses   3,275,356    42,026    -      -    3,317,382 
Depreciation and amortization   770,143    21,052    184,417 (c)   (4,350)(j)   971,262 
General and administrative expenses   13,780,566    657,628    (74,467) (i)   (4,950)(k)   14,358,777 
Total selling, general and administrative expenses   17,826,065    720,706    109,950      (9,300)   18,647,421 
Net (gain) loss on disposition or impairment   86,927    -    -      -    86,927 
Income (loss) from operations   1,431,274    102,019    (191,422)     9,300    1,351,171 
                            
Other income (expense):                           
Bargain purchase gain   19,298    -    -      -    19,298 
Other income (expense), net   (26,771)   37,979    -      -    11,208 
Total other income (expense)   (7,473)   37,979    -      -    30,506 
                            
Income (loss) before income tax expense   1,423,801    139,998    (191,422)     9,300    1,381,677 
                            
Income tax expense   (8,896)   -    - (l)   -    (8,896)
                            
Net income (loss) and comprehensive income (loss)  $1,414,905   $139,998   $(191,422)    $9,300   $1,372,781 
                            
Earnings per share:                           
                            
Basic earnings per share  $0.10                    $0.10 
Diluted earnings per share  $0.10                    $0.10 
                            
Basic weighted average shares   13,774,474                     13,774,474 
Diluted weighted average shares   14,390,320                     14,390,320 

 

 

4

 

THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES

 

NOTES TO UNAUDITED PRO FORMA

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

 

Note 1: Background and Basis of Presentation

 

On July 17, 2019, the Company completed the purchase of the Meglin Clinics for $1,650,000, which consisted of $1,500,000 paid in cash (less $13,450 of deferred revenue) and a $150,000 note issued to the seller.

 

The historical condensed financial statements have been adjusted in the unaudited pro forma condensed combined financial information to give effect to pro forma events that are i) directly attributable to the acquisition and related financing transactions, ii) factually supportable and iii) with respect to the unaudited pro forma condensed combined statements of operations, expected to have a continuing impact on the combined results following the acquisition.

 

The unaudited pro forma condensed combined financial statements are not necessarily indicative of what the Company’s financial position or results of operations would have been had the Company completed the acquisition and related financing transactions at the dates indicated. In addition, the unaudited pro forma condensed combined financial information does not purport to project the future financial position or operating results of the Company after the acquisition. The pro forma information is based on the assumptions, adjustments and eliminations described in the accompanying notes to the unaudited pro forma condensed combined financial statements. The pro forma adjustments are preliminary and are subject to change as more information becomes available and after final analysis of fair values of tangible and intangible assets acquired and liabilities assumed are complete. A final determination of the fair value for certain assets and liabilities will be completed as soon as the information necessary to complete the analysis is obtained, but no later than one year from the acquisition date. Differences between all preliminary estimates included herein and the final acquisition accounting may occur and these differences could be material.

 

Note 2: Estimate of Assets Acquired

 

The acquisition will be accounted for using the acquisition method of accounting in accordance with Accounting Standards Codification 805 - Business Combinations (“ASC 805”), which requires, among other things, that the assets acquired and liabilities assumed be recognized at their acquisition date fair values, with any excess of the consideration transferred over the estimated fair values of the identifiable net assets acquired recorded to goodwill.

 

The total purchase price for the transaction to acquire the Meglin clinics was $1,650,00, less $13,450 of deferred revenue resulting in total purchase consideration of $1,636,550. Total The purchase price consideration was allocated to assets as follows:

 

Property and equipment  $48,418 
Intangible assets   1,072,000 
Operating lease right-of-use asset   511,257 
Operating lease liability - current portion   (86,815)
Operating lease liability - net of current portion   (338,244)
Deferred revenue   (53,928)
Total net assets acquired   1,152,688 
Goodwill   483,862 
Net purchase price  $1,636,550 

 

The pro forma purchase price allocation is subject to further adjustment as additional information becomes available and analyses are completed. The final allocation of amounts to assets acquired and liabilities assumed could differ materially from the preliminary amounts presented in these unaudited pro forma condensed combined financial statements. A decrease in the fair value of assets acquired or an increase in the fair value of liabilities assumed from the preliminary valuations presented in these unaudited pro forma condensed combined financial statements would likely result in a dollar-for-dollar corresponding increase in the amount of goodwill that will result from the acquisition. In addition, if the value of the acquired assets is higher than the preliminary indication, it may result in higher amortization and depreciation expense than is presented in these unaudited pro forma condensed combined financial statements.

 

Intangible assets consist of reacquired franchise rights of $819,000 and customer relationships of $253,000 and will be amortized over their estimated useful lives of three to four years and two years, respectively. These preliminary estimates of fair value and useful lives could be different from the final acquisition accounting, and the difference could have a material impact on the Company’s consolidated financial statements.

 

Note 3: Pro forma adjustments

 

(a)Adjustment to cash and note payable in connection with the purchase consideration paid.

5

 

(b)Adjustment to record property, plant and equipment at the preliminary fair market value which consisted of leasehold improvement of $48,418 to be depreciated over approximately five years.

 

(c)Adjustment to record intangible assets and the related additional amortization expense. Intangible assets consist of reacquired franchise rights of $819,000 amortized over an estimated useful life of three to four years and customer relationships of $253,000 amortized over an estimated useful life of two years.

 

(d)Adjustment to record goodwill as a result of the acquisition. Goodwill represents the excess of the consideration transferred over the preliminary fair value of the assets acquired and liabilities assumed as described in Note 2. The goodwill will not be amortized, but instead will be tested for impairment annually and whenever events and circumstances have occurred that may indicate a possible impairment exists. In the event management determines that the value of goodwill has become impaired, the Company will incur an accounting charge for the amount of the impairment during the period in which the determination is made.

 

(e)Adjustment to record deferred revenue related to the wellness packages sold by the Meglin clinics as a result of the acquisition.

 

(f)Adjustment to eliminate deferred franchise revenue related to the Meglin clinics.

 

(g)Adjustment to eliminate deferred franchise costs and related amortization expense associated with the Meglin clinics.

 

(h)Adjustment to record the impact of the adoption of Accounting Standards Codification 842 – Leases related to assumed leases, resulting in a preliminary estimated fair value of acquired right of use lease assets of $511,257 (including the impact of favorable leases assumed), assumed short-term lease liabilities of $86,815, and long-term lease liabilities of $338,244.

 

(i)Adjustment to eliminate royalty fees (including advertising fee) paid to the Company by the Meglin clinics that are intercompany in nature on a combined basis.

 

(j)Adjustment to eliminate franchise fees recognized by the Company that are intercompany in nature on a combined basis.

 

(k)Adjustment to eliminate software fees paid to the Company by the Meglin clinics that are intercompany in nature on a combined basis.

 

(l)No pro forma adjustment to income taxes was made to the condensed combined statements of operations, as any income tax benefit generated would be fully reserved for, resulting in a net zero impact to income taxes.

 

6